PDPN marks a subset of aggressive and radiation-resistant glioblastoma cells

Treatment-resistant glioma stem cells are thought to propagate and drive growth of malignant gliomas, but their markers and our ability to target them specifically are not well understood. We demonstrate that podoplanin (PDPN) expression is an independent prognostic marker in gliomas across multiple...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in oncology 2022-08, Vol.12, p.941657
Hauptverfasser: Modrek, Aram S, Eskilsson, Eskil, Ezhilarasan, Ravesanker, Wang, Qianghu, Goodman, Lindsey D, Ding, Yingwen, Zhang, Ze-Yan, Bhat, Krishna P L, Le, Thanh-Thuy T, Barthel, Floris P, Tang, Ming, Yang, Jie, Long, Lihong, Gumin, Joy, Lang, Frederick F, Verhaak, Roel G W, Aldape, Kenneth D, Sulman, Erik P
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Treatment-resistant glioma stem cells are thought to propagate and drive growth of malignant gliomas, but their markers and our ability to target them specifically are not well understood. We demonstrate that podoplanin (PDPN) expression is an independent prognostic marker in gliomas across multiple independent patient cohorts comprising both high- and low-grade gliomas. Knockdown of PDPN radiosensitized glioma cell lines and glioma-stem-like cells (GSCs). Clonogenic assays and xenograft experiments revealed that PDPN expression was associated with radiotherapy resistance and tumor aggressiveness. We further demonstrate that knockdown of PDPN in GSCs is sufficient to improve overall survival in an intracranial xenograft mouse model. PDPN therefore identifies a subset of aggressive, treatment-resistant glioma cells responsible for radiation resistance and may serve as a novel therapeutic target.
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.941657